Alan Bank, MD
Cardiovascular Disease · Saint Paul, MNNPI 1063495893
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,398 of the $27,900 with a category attached, or 94.6%. Abbott accounts for 96.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $10,889 and has fallen 96.9% since, to $341 in 2025.
Across 75 payments — averaging $372.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$27K
- Cvrx, Inc.$500
- Medtronic$154
- E.r. Squibb & Sons, L.L.C.$118
- Biosense Webster, Inc.$80
- AstraZeneca$51
- plus $159 from 5 others
Across 95 payments — averaging $6750.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$457K
- Boston Scientific$100K
- Boehringer Ingelheim$34K
- Novartis$31K
- ZOLL Respicardia, Inc.$11K
- Boehringer Ingelheim Pharma GmbH & Co.kg$5K
- plus $4K from 1 others
What the payments were for
- Consulting fees$26,39895%
- Food & beverage$1,5025%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 57 | $26,836 |
| Cvrx, Inc. | 6 | $500 |
| Medtronic(2 entities) | 3 | $154 |
| E.r. Squibb & Sons, L.L.C. | 1 | $118 |
| Biosense Webster, Inc. | 1 | $80 |
| AstraZeneca | 2 | $51 |
| Nuwellis, Inc. | 1 | $46 |
| Boehringer Ingelheim | 1 | $45 |
| Irhythm Technologies, Inc. | 1 | $27 |
| Boston Scientific | 1 | $27 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FlexAbility Ablation Catheter$7,656
- RhythmVIEW Work Stations$5,808
- TactiCath Quartz CFA Catheter$5,630
- FLEXABILITY$2,816
- CRM-Research only$1,584
- AMPLATZER Occluders$1,056
- Cardiovascular- Research only$880
- Mitra Clip system$704
- Barostim Neo System$444
- ZEPOSIA$118
- ENSITE PRECISION$100
How this compares
$27,900 in reported general payments places this provider in the 80th percentile of 451 cardiovascular disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 22 | $473,687 |
| EliquisApixaban | 176 | $239,407 |
| EntrestoSacubitril/Valsartan | 93 | $138,415 |
| FarxigaDapagliflozin Propanediol | 97 | $114,938 |
| XareltoRivaroxaban | 101 | $109,201 |
| JardianceEmpagliflozin | 86 | $107,853 |
| Metoprolol Succinate | 392 | $7,930 |
| Potassium Chloride | 162 | $5,779 |
| Bumetanide | 49 | $3,824 |
| Torsemide | 78 | $3,527 |
| Atorvastatin Calcium | 225 | $3,281 |
| Furosemide | 323 | $3,110 |
| Lisinopril | 184 | $2,596 |
| Losartan Potassium | 178 | $2,459 |
| Carvedilol | 183 | $2,148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $15 | $713,094198 claims |
| AstraZenecaFarxiga | $51 | $114,93897 claims |
| Boehringer IngelheimJardiance | $45 | $107,85386 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 451 cardiovascular disease providers in Minnesota.
Other cardiovascular disease in Saint Paul
- Thomas BiggsSaint Paul$244K
- Pierce VatterottSaint Paul$146K
- Spencer KuboSaint Paul$134K
- Johannes BrechtkenSaint Paul$100K
- Nishtha SodhiSaint Paul$50K
- Jeffrey ChambersMinneapolis$3.2M
- Srijoy MahapatraRochester$1.2M
- Markus MeyerMinneapolis$786K
- Robert SchwartzMinneapolis$502K
- Robert VantasselMinneapolis$493K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.